Pfizer nears $14 billion deal for Medivation

(Reuters) - Pfizer Inc is in advanced talks to acquire U.S. cancer drug company Medivation Inc for close to $14 billion, as it seeks to boost its oncology portfolio, a person familiar with the matter said on Sunday.

Pfizer nears $14 billion deal for Medivation
Read More


Bagikan Berita Ini